BioMarin

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. 

CEO
Alexander Hardy
CEOAlexander Hardy
Employees
3,221
Employees3,221
Headquarters
San Rafael, California
HeadquartersSan Rafael, California
Founded
1997
Founded1997
Employees
3,221
Employees3,221

BMRN Key Statistics

Market cap
11.27B
Market cap11.27B
Price-Earnings ratio
155.00
Price-Earnings ratio155.00
Dividend yield
—
Dividend yield—
Average volume
2.51M
Average volume2.51M
High today
$59.37
High today$59.37
Low today
$57.70
Low today$57.70
Open price
$58.40
Open price$58.40
Volume
1.11M
Volume1.11M
52 Week high
$70.98
52 Week high$70.98
52 Week low
$49.26
52 Week low$49.26

Stock Snapshot

BioMarin(BMRN) stock is priced at $58.23, giving the company a market capitalization of 11.27B. It carries a P/E multiple of 155.00.

On 2026-10-30, BioMarin(BMRN) stock traded between a low of $57.70 and a high of $59.37. Shares are currently priced at $58.23, which is +0.9% above the low and -1.9% below the high.

BioMarin(BMRN) shares are trading with a volume of 1.11M, against a daily average of 2.51M.

In the last year, BioMarin(BMRN) shares hit a 52-week high of $70.98 and a 52-week low of $49.26.

In the last year, BioMarin(BMRN) shares hit a 52-week high of $70.98 and a 52-week low of $49.26.

BMRN News

Investing.com 1d
BioMarin licenses Fabry disease therapy for $70M upfront - Investing.com

...

BioMarin licenses Fabry disease therapy for $70M upfront - Investing.com
Simply Wall St 3d
BioMarin Pharmaceutical Could Be 24% Undervalued Ahead Of Its November 2 Results Call

Advertisement Event overview and why it matters for BioMarin Pharmaceutical investors BioMarin Pharmaceutical (BMRN) has scheduled a conference call and webca...

Analyst ratings

77%

of 31 ratings
Buy
77.4%
Hold
22.6%
Sell
0%

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.